Advertisement
Advertisement
U.S. markets closed
S&P Futures
4,271.00 -10.00 (-0.23%) Dow Futures
33,647.00 -71.00 (-0.21%) Nasdaq Futures
13,544.75 -33.00 (-0.24%) Russell 2000 Futures
2,011.80 -5.10 (-0.25%) Crude Oil
91.84 -0.25 (-0.27%) Gold
1,816.40 +0.90 (+0.05%)
At close: 04:00PM EDT
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Performance Outlook
| Previous Close | 69.56 |
| Open | 69.46 |
| Bid | 70.04 x 1100 |
| Ask | 70.08 x 800 |
| Day's Range | 69.03 - 70.18 |
| 52 Week Range | 63.92 - 88.78 |
| Volume | |
| Avg. Volume | 789,817 |
| Market Cap | 34.34B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 76.16 |
| EPS (TTM) | 0.92 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.21 (0.30%) |
| Ex-Dividend Date | May 03, 2022 |
| 1y Target Est | 85.83 |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-38% Est. Return
Subscribe to Yahoo Finance Plus to view Fair Value for ALC
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
- Alcon Inc.Analyst Report: Alcon Inc.Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.RatingFair ValueEconomic Moat5 days agoMorningstar
- Zacks
Alcon (ALC) Q2 Earnings Surpass Estimates, Guidance Lowered
Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the successful launch of new ATIOL roles and SiHy contact lenses.
- Business Wire
Alcon Reports Second Quarter 2022 Results
GENEVA, August 09, 2022--Alcon Reports Second Quarter 2022 Results
- Zacks
CVS Health (CVS) to Report Q2 Earnings: What's in the Cards?
Robust retail and pharmacy sales performance are likely to have driven CVS Health's (CVS) Q2 performance.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
